Kobayashi Takayuki, Uehara Yuji, Watanabe Kageaki, Hishima Tsunekazu, Hosomi Yukio
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
JTO Clin Res Rep. 2023 Jun 15;4(7):100538. doi: 10.1016/j.jtocrr.2023.100538. eCollection 2023 Jul.
ALK-positive large-cell neuroendocrine carcinoma (LCNEC) is an exceptionally rare form of lung cancer. The efficacy of ALK inhibitors in treating ALK-positive LCNEC remains unclear. Here, we report a case of ALK-positive LCNEC of the lung, which revealed a sustained clinical benefit (24+ mo of overall survival) after treatment with sequential ALK inhibitors and local therapies. This remarkable improvement in survival underscores the importance of testing metastatic LCNEC for biomarkers, such as rearrangement, using immunohistochemistry or next-generation sequencing, especially in younger patients.
间变性淋巴瘤激酶（ALK）阳性大细胞神经内分泌癌（LCNEC）是一种极其罕见的肺癌形式。ALK抑制剂治疗ALK阳性LCNEC的疗效尚不清楚。在此，我们报告一例肺部ALK阳性LCNEC病例，该病例在序贯使用ALK抑制剂和局部治疗后显示出持续的临床获益（总生存期达24个月以上）。生存情况的显著改善凸显了对转移性LCNEC进行生物标志物检测的重要性，例如使用免疫组织化学或二代测序检测重排情况，尤其是在年轻患者中。
